Philadelphia’s transit agency has sued Gilead Sciences Inc., accusing the company of “price-gouging” on the sale of its $1,000-per-pill hepatitis C drug Sovaldi, the latest salvo in a battle between health-care payers and the pharmaceutical industry over prices.. The Southeastern Pennsylvania Transportation Authority, or Septa, filed the lawsuit on Tuesday in U.S. District Court for the Eastern District of Pennsylvania. The suit seeks class-action status, subject to certification by a judge, on behalf of any person or entity...
  